Company intelligence / Profile preview

Invitrolize

Ownership: Private
Development stage: Preclinical

Overview

Invitrolize has developed ALIsens®, the first in vitro alveolar model capable of identifying and differentiating respiratory sensitizers and irritants under realistic air-liquid interface exposure conditions. The technology is validated for toxicological testing, shows high specificity (>95%), and is being positioned as a new regulatory standard. It enables early hazard assessment without animal testing and is already seeing strong commercial traction across Europe, the US, and Asia[1][2][3][5].

Therapeutic areas: Pulmonology
Modalities: In vitro modelDevice (in the context of laboratory testing platforms)
Industry: Non-Drug Biotech

Partnerships

Luxembourg Institute of Science and Technology (LIST) [technology originator/supporter]

Beyond the preview

Go deeper on Invitrolize.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Invitrolize.

Explore the full profile